MN HF4034

Renames Minnesota's Right to Try Act to "Right to Try Act 2.0" and shifts focus from general investigational drugs to individualized treatments created specifically for individual patients based on their genetic profile, including gene therapy antisense oligonucleotides and neoantigen vaccines

Expands patient eligibility from those with terminal illness to include patients with "life-threatening" or "severely debilitating" illnesses as defined in federal regulations

Requires physician recommendations for individualized treatments to be based on analysis of the patient's genomic sequence, DNA, RNA, genes, gene products, or metabolites

Prohibits manufacturers from collecting treatment costs from a patient's heirs or estate if the patient dies during treatment

Maintains existing protections: manufacturers are not required to provide treatments, health care providers are shielded from disciplinary action, and insurance coverage is not mandated for these treatments